FLT3 and acute myeloid leukemia: Results from our FLT3 mutant xenograft model demonstrate a synergy between OTS167 and gilteritinib in vivo, suggesting potential therapeutic value for OTS167 and a path forward for future dual agent targeting in FLT3 mutant AML.